Medicines for Malaria Venture (MMV)
@mmv.org
A leading global health partnership working to reduce the burden of malaria. We discover, develop and deliver new antimalarial medicines.
Our response to antimalarial drug resistance will shape the future of #malaria control & elimination. Ganaplacide-lumefantrine, a novel non-artemisinin combination developed by @novartis.bsky.social with MMV, can tackle drug-resistant parasites. Prof. Djimdé explains how on BBC
👉 bit.ly/4qaHQLU
👉 bit.ly/4qaHQLU
January 14, 2026 at 1:19 PM
Our response to antimalarial drug resistance will shape the future of #malaria control & elimination. Ganaplacide-lumefantrine, a novel non-artemisinin combination developed by @novartis.bsky.social with MMV, can tackle drug-resistant parasites. Prof. Djimdé explains how on BBC
👉 bit.ly/4qaHQLU
👉 bit.ly/4qaHQLU
Calling all mid-career African researchers: the application deadline for the SAHRI Fellowship Programme is fast approaching. A fully funded opportunity to build leadership in biomedical innovation and clinical research. Apply by 1 February bit.ly/4qfTdT6
January 13, 2026 at 5:13 PM
Calling all mid-career African researchers: the application deadline for the SAHRI Fellowship Programme is fast approaching. A fully funded opportunity to build leadership in biomedical innovation and clinical research. Apply by 1 February bit.ly/4qfTdT6
Can #AI accelerate the discovery of next-gen antimalarials to keep us ahead of resistance and bring us closer to zero #malaria deaths? Sithulisiwe Ngwenya explains how dd4gh, an AI-powered platform in development by MMV & @deepmirror.bsky.social, can support her drug discovery research.
January 13, 2026 at 2:48 PM
Can #AI accelerate the discovery of next-gen antimalarials to keep us ahead of resistance and bring us closer to zero #malaria deaths? Sithulisiwe Ngwenya explains how dd4gh, an AI-powered platform in development by MMV & @deepmirror.bsky.social, can support her drug discovery research.
How can we go farther and faster together in the fight against #malaria? By leaning into our role as impatient optimists.
At #ASTMH25, MMV and @gatesfoundation.bsky.social reaffirmed our belief in a malaria-free future and a bold, science-driven path forward. 🎥 bit.ly/44OOyOP
At #ASTMH25, MMV and @gatesfoundation.bsky.social reaffirmed our belief in a malaria-free future and a bold, science-driven path forward. 🎥 bit.ly/44OOyOP
January 9, 2026 at 9:12 AM
How can we go farther and faster together in the fight against #malaria? By leaning into our role as impatient optimists.
At #ASTMH25, MMV and @gatesfoundation.bsky.social reaffirmed our belief in a malaria-free future and a bold, science-driven path forward. 🎥 bit.ly/44OOyOP
At #ASTMH25, MMV and @gatesfoundation.bsky.social reaffirmed our belief in a malaria-free future and a bold, science-driven path forward. 🎥 bit.ly/44OOyOP
Working on a project that could help expand MMV’s drug discovery pipeline and the global antimalarial toolbox? Our 23rd call for proposals is now open for compounds addressing key #malaria prevention, treatment and elimination needs. Deadline: 27 Feb. 👉 bit.ly/3XFUG8n
January 7, 2026 at 1:21 PM
Working on a project that could help expand MMV’s drug discovery pipeline and the global antimalarial toolbox? Our 23rd call for proposals is now open for compounds addressing key #malaria prevention, treatment and elimination needs. Deadline: 27 Feb. 👉 bit.ly/3XFUG8n
Despite setbacks & emerging threats, progress against #malaria continues.
Since 2000, billions of cases & millions of deaths have been averted & more countries are now malaria-free. Cabo Verde, Egypt, Georgia, Suriname & Timor-Leste show that zero malaria is possible.
Since 2000, billions of cases & millions of deaths have been averted & more countries are now malaria-free. Cabo Verde, Egypt, Georgia, Suriname & Timor-Leste show that zero malaria is possible.
January 7, 2026 at 11:04 AM
Despite setbacks & emerging threats, progress against #malaria continues.
Since 2000, billions of cases & millions of deaths have been averted & more countries are now malaria-free. Cabo Verde, Egypt, Georgia, Suriname & Timor-Leste show that zero malaria is possible.
Since 2000, billions of cases & millions of deaths have been averted & more countries are now malaria-free. Cabo Verde, Egypt, Georgia, Suriname & Timor-Leste show that zero malaria is possible.
Scenes from last week’s co-creation workshop in Accra, where MMV & @deepmirror.bsky.social convened a group of Africa-based researchers convened to learn about & shape the continued development of the AI-powered Drug Discovery for Global Health platform. More 👉 bit.ly/4qeyz55
December 19, 2025 at 2:09 PM
Scenes from last week’s co-creation workshop in Accra, where MMV & @deepmirror.bsky.social convened a group of Africa-based researchers convened to learn about & shape the continued development of the AI-powered Drug Discovery for Global Health platform. More 👉 bit.ly/4qeyz55
Children’s medicines lag nearly a decade behind adult treatments.
@who.int’s GAP-f network is working to close this gap. Its recent #malaria PADO exercise – supported by MMV – set a research agenda to better address children’s needs.
Report 👉 bit.ly/4pyfMBN
@who.int’s GAP-f network is working to close this gap. Its recent #malaria PADO exercise – supported by MMV – set a research agenda to better address children’s needs.
Report 👉 bit.ly/4pyfMBN
December 19, 2025 at 1:20 PM
Children’s medicines lag nearly a decade behind adult treatments.
@who.int’s GAP-f network is working to close this gap. Its recent #malaria PADO exercise – supported by MMV – set a research agenda to better address children’s needs.
Report 👉 bit.ly/4pyfMBN
@who.int’s GAP-f network is working to close this gap. Its recent #malaria PADO exercise – supported by MMV – set a research agenda to better address children’s needs.
Report 👉 bit.ly/4pyfMBN
This year proved we can regain momentum against #malaria. To defeat it, we need broader access and new #innovations. MMV's CEO Martin Fitchet shares what’s needed in 2026 to accelerate progress through innovation & partnership.
December 19, 2025 at 12:21 PM
This year proved we can regain momentum against #malaria. To defeat it, we need broader access and new #innovations. MMV's CEO Martin Fitchet shares what’s needed in 2026 to accelerate progress through innovation & partnership.
A powerful trio of #malaria prevention tools – vector control, chemoprevention & vaccines – helped protect millions last year.
MMV works with national malaria control programmes & African manufacturers to continue expanding access to SMC for children and pregnant women.
MMV works with national malaria control programmes & African manufacturers to continue expanding access to SMC for children and pregnant women.
December 18, 2025 at 1:51 PM
A powerful trio of #malaria prevention tools – vector control, chemoprevention & vaccines – helped protect millions last year.
MMV works with national malaria control programmes & African manufacturers to continue expanding access to SMC for children and pregnant women.
MMV works with national malaria control programmes & African manufacturers to continue expanding access to SMC for children and pregnant women.
The #WorldMalariaReport is clear: drug resistance is advancing. Our response must be just as clear: new meds with new mechanisms of action.
Collaboration, commitment & funding can keep us ahead of resistance & help deliver next-gen meds to ensure #malaria is no longer a threat.
Collaboration, commitment & funding can keep us ahead of resistance & help deliver next-gen meds to ensure #malaria is no longer a threat.
December 18, 2025 at 1:49 PM
The #WorldMalariaReport is clear: drug resistance is advancing. Our response must be just as clear: new meds with new mechanisms of action.
Collaboration, commitment & funding can keep us ahead of resistance & help deliver next-gen meds to ensure #malaria is no longer a threat.
Collaboration, commitment & funding can keep us ahead of resistance & help deliver next-gen meds to ensure #malaria is no longer a threat.
Antimalarial drug resistance won’t wait, and neither should we. At the #WorldMalariaReport launch in the UK Parliament, MMV’s Cristina Donini highlighted our efforts to stay one step ahead of resistance and the role UK science & innovation play in the fight against #malaria.
December 16, 2025 at 1:55 PM
Antimalarial drug resistance won’t wait, and neither should we. At the #WorldMalariaReport launch in the UK Parliament, MMV’s Cristina Donini highlighted our efforts to stay one step ahead of resistance and the role UK science & innovation play in the fight against #malaria.
The @who.int 2025 World malaria report brings a clear message: drug resistance threatens to undo hard-won gains against #malaria. With progress stalling, we must double down on innovation, surveillance and long-term commitment to stay ahead of resistance 👉 bit.ly/48JynVs
December 4, 2025 at 9:30 AM
The @who.int 2025 World malaria report brings a clear message: drug resistance threatens to undo hard-won gains against #malaria. With progress stalling, we must double down on innovation, surveillance and long-term commitment to stay ahead of resistance 👉 bit.ly/48JynVs
On International Day of Persons with Disabilities. MMV is proud to be part of the @who.int Disability Health Equity Network. The relationships built through the network will help us define what disability inclusion means for MMV. #IDPD #DisabilityDay #Malaria #GlobalHealth
December 3, 2025 at 8:42 AM
On International Day of Persons with Disabilities. MMV is proud to be part of the @who.int Disability Health Equity Network. The relationships built through the network will help us define what disability inclusion means for MMV. #IDPD #DisabilityDay #Malaria #GlobalHealth
#ClimateChange is expanding #malaria-risk zones across Africa, a new Global Change Biology study warns, potentially putting millions more at risk. We need innovative, accessible tools to stay ahead 👉 bit.ly/4iyhTTu
December 2, 2025 at 11:14 AM
#ClimateChange is expanding #malaria-risk zones across Africa, a new Global Change Biology study warns, potentially putting millions more at risk. We need innovative, accessible tools to stay ahead 👉 bit.ly/4iyhTTu
How do #malaria parasites survive in the mosquito gut?
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
November 28, 2025 at 3:27 PM
How do #malaria parasites survive in the mosquito gut?
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
Press release 📢 Announcing MMV's new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for #malaria prevention.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
November 27, 2025 at 1:08 PM
Press release 📢 Announcing MMV's new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for #malaria prevention.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
Vivax #malaria relapses keep patients trapped in a cycle. The Partnership for Vivax Elimination (PAVE) has been generating evidence from across endemic countries to support country elimination goals.
November 27, 2025 at 11:27 AM
Vivax #malaria relapses keep patients trapped in a cycle. The Partnership for Vivax Elimination (PAVE) has been generating evidence from across endemic countries to support country elimination goals.
Is #malaria eradication still within reach?
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
November 26, 2025 at 12:53 PM
Is #malaria eradication still within reach?
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25
November 24, 2025 at 9:36 PM
Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25
At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance.
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
November 24, 2025 at 4:21 PM
At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance.
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future.
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
November 21, 2025 at 7:04 PM
Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future.
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P
November 13, 2025 at 7:26 AM
For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P
This week at #ASTMH25, the Partnership for Vivax Elimination (PAVE) network came together to show what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.
November 12, 2025 at 10:16 PM
This week at #ASTMH25, the Partnership for Vivax Elimination (PAVE) network came together to show what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.